Verastem (VSTM) Reports Q1 Loss of $0.46/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Verastem to Present at 2015 UBS Global Health Care Conference
May 12, 2015 7:00 AM EDTBOSTON--(BUSINESS WIRE)-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the company will present at the 2015 UBS Global Healthcare Conference on Tuesday, May 19 at... More
Verastem Reports First Quarter 2015 Financial and Corporate Results
May 11, 2015 4:05 PM EDTCOMMAND Interim Analysis Anticipated in Third Quarter 2015
BOSTON--(BUSINESS WIRE)-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today reported financial results for the first quarter ended March 31, 2015, and also provided an overview of certain corporate accomplishments and plans.
The team continues to efficiently execute on each of our ongoing programs targeting cancer stem cells, said Robert Forrester, President and Chief Executive Officer of Verastem. Accrual to the COMMAND study evaluating our cancer stem cell inhibitor, VS-6063, as a switch... More
